Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G1090N in healthy subjects
NCT07110441Phase 1Completed
- Sponsor
- Genfit
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of G1090N in acute-on-chronic liver failure (ACLF) (4 arms), sponsored by Genfit. Primary endpoints: Maximum Concentration, Time to Maximum Concentration and 5 more. Started Aug 2025; status: completed.
02
Drugs
G1090N
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT07110441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110441.